Full text is available at the source.
Abstract
Tirzepatide is increasingly used in overweight and obese individuals with type 1 diabetes.
- The effect of tirzepatide on diabetic retinopathy (DR) and diabetic macular edema (DME) is currently unknown.
- There is a need to investigate whether tirzepatide impacts the incidence and progression of DR in type 1 diabetes.
- Understanding the relationship between tirzepatide and DR could inform treatment strategies for individuals with type 1 diabetes.
Simplified